Overview

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if either a targeted type of talk therapy (Phase I) or medication, Wellbutrin, (Phase II) improve sleep disturbance and/or fatigue in individuals with Inflammatory Bowel Disease (IBD).
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Eva Szigethy
University of Pittsburgh
Collaborator:
Crohn's and Colitis Foundation
Treatments:
Bupropion
Criteria
Inclusion Criteria:

- IBD Group:

- Biopsy confirmed Crohn's Disease

- Qualifying scores on Multidimensional Fatigue Inventory and Pittsburgh Sleep
Quality Index

- Healthy Volunteer Group:

- Does not meet any exclusion criteria

Exclusion Criteria:

- IBD Group:

- Meeting criteria for active alcohol or substance abuse or dependence

- Current ongoing treatment with Wellbutrin

- Females who are pregnant or plan to become pregnant within three months

- Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive
airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)

- Current IBD flare requiring hospitalization with intravenous steroid treatment

- Other acute medical conditions or a history of chronic inflammatory condition
other than IBD

- Hemoglobin <10 with age and gender adjustments

- History of seizure disorder

- Acute infection within seven days

- Healthy Volunteer Group:

- History or current episode of psychiatric disorder by Diagnositic and Statistical
Manual (DSM-IV)

- Current ongoing treatment with psychoactive medications

- Medications for sleep in previous two weeks

- Females who are pregnant or plan to become pregnant within three months

- History of IBD, epilepsy, rheumatoid arthritis, lupus

- Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive
airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)